GSK (GSK) shares rose in early trading on Tuesday after the US Food and Drug Administration published documents related to a potential approval of the company's blood cancer drug, Bloomberg reported.
The FDA's Oncologic Drugs Advisory Committee is scheduled to meet on Thursday to discuss GSK's Blenrep, Bloomberg reported, adding that a decision on approval of the drug is expected by July 23.
Blenrep has been approved in the UK in combination with other oncology drugs to treat certain patients with multiple myeloma, an incurable blood cancer, Bloomberg reported.
GSK shares were 0.7% higher in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 38.54, Change: +0.24, Percent Change: +0.63
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.